Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

PR Newswire October 6, 2022

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

PR Newswire September 29, 2022

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

PR Newswire September 12, 2022

Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

PR Newswire August 12, 2021

Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th

PR Newswire July 7, 2021

Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th

PR Newswire June 22, 2021

Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June

PR Newswire June 14, 2021

Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches

PR Newswire June 4, 2021

Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

PR Newswire May 13, 2021

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

PR Newswire May 11, 2021

Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings

PR Newswire April 29, 2021

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL(TM) RNAi Targeting PD-1

PR Newswire April 10, 2021

Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update

PR Newswire March 25, 2021

Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire March 11, 2021

Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies

PR Newswire March 1, 2021

Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th

PR Newswire February 23, 2021

Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

PR Newswire February 17, 2021

Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market

PR Newswire February 12, 2021

Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market

PR Newswire January 25, 2021

Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market

PR Newswire January 21, 2021